Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Don D Sin

Showing results (41-50 of 629) with videos related to

Pageof 63
Sort By:
ERJ Open Research|April 8, 2025
Should all patients with COPD be treated with inhaled triple therapy?Don D Sin, Mohsen Sadatsafavi
The Lancet. Respiratory Medicine|April 14, 2018
Crisis of COPD in China: the future is nowYilan Sun, Don D Sin
Evidence-Based Medicine|September 28, 2011
Inhaled anticholinergic medications in older men with chronic obstructive pulmonary disorder are associated with increased odds of acute urinary retentionRobert Kyskan, Don D Sin
International Journal of Chronic Obstructive Pulmonary Disease|August 5, 2011
Improved patient outcome with smoking cessation: when is it too late?Jane Wu, Don D Sin
The Medical Clinics of North America|July 17, 2012
Pathobiologic mechanisms of chronic obstructive pulmonary diseaseAnthony Tam, Don D Sin
Archivos De Bronconeumologia|April 12, 2025
How Should We Treat COPD Exacerbations in the Future? By Endophenotyping, Of Course!Clarus Leung, Don D Sin
The European Respiratory Journal|March 14, 2024
Type 2 airway inflammation in COPDFrancesca Polverino, Don D Sin
Lancet (London, England)|May 18, 2026
Astegolimab and the new era of biologics in COPD careClarus Leung, Don D Sin
The European Respiratory Journal|June 18, 2026
Large scale plasma proteomics: opening up new frontiers of biomarker and therapeutic target discoveries in COPDXuekui Zhang, Don D Sin
The European Respiratory Journal|June 11, 2021
Methylxanthines in COPD: yes to caffeine, no to theophyllineKen M Kunisaki, Don D Sin
Pageof 63

Showing results (41-50 of 629) with videos related to

Sort By:
Pageof 63
ERJ Open Research|April 8, 2025
Should all patients with COPD be treated with inhaled triple therapy?Don D Sin, Mohsen Sadatsafavi
The Lancet. Respiratory Medicine|April 14, 2018
Crisis of COPD in China: the future is nowYilan Sun, Don D Sin
Evidence-Based Medicine|September 28, 2011
Inhaled anticholinergic medications in older men with chronic obstructive pulmonary disorder are associated with increased odds of acute urinary retentionRobert Kyskan, Don D Sin
International Journal of Chronic Obstructive Pulmonary Disease|August 5, 2011
Improved patient outcome with smoking cessation: when is it too late?Jane Wu, Don D Sin
The Medical Clinics of North America|July 17, 2012
Pathobiologic mechanisms of chronic obstructive pulmonary diseaseAnthony Tam, Don D Sin
Archivos De Bronconeumologia|April 12, 2025
How Should We Treat COPD Exacerbations in the Future? By Endophenotyping, Of Course!Clarus Leung, Don D Sin
The European Respiratory Journal|March 14, 2024
Type 2 airway inflammation in COPDFrancesca Polverino, Don D Sin
Lancet (London, England)|May 18, 2026
Astegolimab and the new era of biologics in COPD careClarus Leung, Don D Sin
The European Respiratory Journal|June 18, 2026
Large scale plasma proteomics: opening up new frontiers of biomarker and therapeutic target discoveries in COPDXuekui Zhang, Don D Sin
The European Respiratory Journal|June 11, 2021
Methylxanthines in COPD: yes to caffeine, no to theophyllineKen M Kunisaki, Don D Sin
Pageof 63